Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Cell-based therapy for Crohn’s disease: time to consider optimization

Nature Reviews Gastroenterology & Hepatology volume 16, pages 137–138 (2019)Cite this article

Subjects

Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Factors influencing efficacy of mesenchymal stem cell therapy for Crohn’s disease.

References

  1. Schwartz, D. A. et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122, 875–880 (2002).

    Article  Google Scholar 

  2. Park, S. H. et al. Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izy329 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Horton, J. A. et al. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells 31, 2231–2241 (2013).

    Article  CAS  Google Scholar 

  4. Mayne, C. G. & Williams, C. B. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm. Bowel Dis. 19, 1772–1788 (2013).

    Article  Google Scholar 

  5. Lightner, A. L. et al. Systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn’s disease: progress made and future directions. Dis. Colon Rectum 61, 629–640 (2018).

    Article  Google Scholar 

  6. Lo Surdo, J. L., Millis, B. A. & Bauer, S. R. Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells. Cytotherapy 15, 1527–1540 (2013).

    Article  CAS  Google Scholar 

  7. Serena, C. et al. Crohn’s disease disturbs the immune properties of human adipose-derived stem cells related to inflammasome activation. Stem Cell Reports 9, 1109–1123 (2017).

    Article  CAS  Google Scholar 

  8. Yu, H. et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment. Pharmacol. Ther. 47, 364–370 (2018).

    Article  CAS  Google Scholar 

  9. D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008).

    Article  Google Scholar 

  10. Wyles, C. C. et al. Differential cytotoxicity of corticosteroids on human mesenchymal stem cells. Clin. Orthop. Relat. Res. 473, 1155–1164 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA

    Amy L. Lightner

Authors
  1. Amy L. Lightner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy L. Lightner.

Ethics declarations

Competing interests

The author has acted as a consultant for Takeda.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lightner, A.L. Cell-based therapy for Crohn’s disease: time to consider optimization. Nat Rev Gastroenterol Hepatol 16, 137–138 (2019). https://doi.org/10.1038/s41575-018-0095-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-018-0095-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing